The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Summary

This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.

Timeline

Start

2023-01-19

Primary completion

2024-12-01

Completion

2024-12-23

Drugs

Indications